首页 > 最新文献

Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences最新文献

英文 中文
Polyherbal combination for wound healing: Matricaria chamomilla L. and Punica granatum L. 用于伤口愈合的多草药组合:洋甘菊和石榴
Pub Date : 2021-06-01 Epub Date: 2021-05-09 DOI: 10.1007/s40199-021-00392-x
Somayeh Niknam, Zahra Tofighi, Mohammad Ali Faramarzi, Mohammad Amin Abdollahifar, Ensieh Sajadi, Rassoul Dinarvand, Tayebeh Toliyat

Background: Punica granatum L. (pomegranate) with astringent activities and Matricaria chamomilla L. (chamomile) with anti-inflammatory and antioxidant properties are natural remedies used for various skin disorders, including wound healing.

Objectives: This study was conducted to evaluate the individual and combined wound healing activity of the methanol extracts of pomegranate and chamomile flowers.

Methods: After preparing the menthol fraction of pomegranate and chamomile flowers, the content of total phenols, total tannins, and total flavonoids of fractions was measured. For standardization of pomegranate and chamomile fractions, Gallic acid and apigenin-7-O-glucoside contents of them were determined using high-performance liquid chromatography (HPLC). Moreover, their antioxidant activities were examined using DPPH and FRAP tests. The antimicrobial assay was performed against Staphylococcus aureus, Staphylococcus epidermidis, and Pseudomonas aeruginosa. Three different concentrations of methanol fraction of each plant and one combination dose of fractions were investigated for their wound healing activities in an excision wound model on the rats' dorsum. Finally, histopathological studies were done at the end of the experiment.

Results: Phytochemical examinations showed high amounts of phenolic compounds in pomegranate flowers, while chamomile flower fractions contained a high amount of total flavonoids. Both fractions, especially pomegranate, had potent antioxidant activity. The best results for wound closure were observed 7 days after wound induction. All treated groups exhibited superior wound contraction compared to their placebo at all measurement times. The combined form of pomegranate and chamomile had better wound healing properties compared to a single therapy, especially on time earlier to wound induction.

Conclusion: This study represented high antioxidant and wound healing activities for methanol fraction of pomegranate and chamomile flowers, which could be related to their high content of phytochemicals. In comparison with single herb treatment, the combined form of these two fractions in lower concentrations accelerated wound closure.

背景:具有收敛活性的石榴(Punica granatum L.)和具有抗炎和抗氧化特性的洋甘菊(Matricaria chamomilla L.)是治疗各种皮肤疾病(包括伤口愈合)的天然药物:本研究旨在评估石榴花和洋甘菊花甲醇提取物的单独和联合伤口愈合活性:方法:制备石榴花和洋甘菊花的薄荷醇馏分后,测定馏分中总酚、总鞣质和总黄酮类化合物的含量。为了对石榴和洋甘菊馏分进行标准化,使用高效液相色谱法(HPLC)测定了它们的没食子酸和芹菜素-7-O-葡萄糖苷含量。此外,还使用 DPPH 和 FRAP 试验检测了它们的抗氧化活性。对金黄色葡萄球菌、表皮葡萄球菌和绿脓杆菌进行了抗菌试验。在大鼠背部切除伤口模型中,研究了每种植物的三种不同浓度的甲醇馏分和一种馏分组合剂量的伤口愈合活性。最后,在实验结束时进行了组织病理学研究:植物化学检查显示,石榴花中含有大量酚类化合物,而甘菊花馏分则含有大量总黄酮。两种馏分,尤其是石榴花,都具有很强的抗氧化活性。伤口诱导 7 天后,伤口闭合效果最佳。在所有测量时间内,所有治疗组的伤口收缩效果都优于安慰剂组。与单一疗法相比,石榴和甘菊的组合疗法具有更好的伤口愈合特性,尤其是在伤口诱导的早期:本研究表明,石榴花和洋甘菊花的甲醇馏分具有较高的抗氧化和伤口愈合活性,这可能与它们的植物化学成分含量较高有关。与单一草药治疗相比,这两种馏分的低浓度组合形式可加速伤口愈合。
{"title":"Polyherbal combination for wound healing: Matricaria chamomilla L. and Punica granatum L.","authors":"Somayeh Niknam, Zahra Tofighi, Mohammad Ali Faramarzi, Mohammad Amin Abdollahifar, Ensieh Sajadi, Rassoul Dinarvand, Tayebeh Toliyat","doi":"10.1007/s40199-021-00392-x","DOIUrl":"10.1007/s40199-021-00392-x","url":null,"abstract":"<p><strong>Background: </strong>Punica granatum L. (pomegranate) with astringent activities and Matricaria chamomilla L. (chamomile) with anti-inflammatory and antioxidant properties are natural remedies used for various skin disorders, including wound healing.</p><p><strong>Objectives: </strong>This study was conducted to evaluate the individual and combined wound healing activity of the methanol extracts of pomegranate and chamomile flowers.</p><p><strong>Methods: </strong>After preparing the menthol fraction of pomegranate and chamomile flowers, the content of total phenols, total tannins, and total flavonoids of fractions was measured. For standardization of pomegranate and chamomile fractions, Gallic acid and apigenin-7-O-glucoside contents of them were determined using high-performance liquid chromatography (HPLC). Moreover, their antioxidant activities were examined using DPPH and FRAP tests. The antimicrobial assay was performed against Staphylococcus aureus, Staphylococcus epidermidis, and Pseudomonas aeruginosa. Three different concentrations of methanol fraction of each plant and one combination dose of fractions were investigated for their wound healing activities in an excision wound model on the rats' dorsum. Finally, histopathological studies were done at the end of the experiment.</p><p><strong>Results: </strong>Phytochemical examinations showed high amounts of phenolic compounds in pomegranate flowers, while chamomile flower fractions contained a high amount of total flavonoids. Both fractions, especially pomegranate, had potent antioxidant activity. The best results for wound closure were observed 7 days after wound induction. All treated groups exhibited superior wound contraction compared to their placebo at all measurement times. The combined form of pomegranate and chamomile had better wound healing properties compared to a single therapy, especially on time earlier to wound induction.</p><p><strong>Conclusion: </strong>This study represented high antioxidant and wound healing activities for methanol fraction of pomegranate and chamomile flowers, which could be related to their high content of phytochemicals. In comparison with single herb treatment, the combined form of these two fractions in lower concentrations accelerated wound closure.</p>","PeriodicalId":10961,"journal":{"name":"Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences","volume":"29 1","pages":"133-145"},"PeriodicalIF":0.0,"publicationDate":"2021-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8149548/pdf/40199_2021_Article_392.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38894110","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Surging trends in prescriptions and costs of antidepressants in England amid COVID-19. 在2019冠状病毒病期间,英格兰抗抑郁药的处方和成本呈飙升趋势。
Pub Date : 2021-06-01 Epub Date: 2021-03-13 DOI: 10.1007/s40199-021-00390-z
Shahad A Rabeea, Hamid A Merchant, Muhammad Umair Khan, Chia Siang Kow, Syed Shahzad Hasan

The social restrictions amid coronavirus disease 2019 (COVID-19) pandemic have posed a serious threat to mental health and have implications in the use of medications for mental health including antidepressants (ADs). This study investigated the trends in prescriptions and costs of various ADs in England during COVID-19 pandemic. National prescribing rates and net ingredient costs (NIC) of all ADs prescriptions during 2016 to 2020 were analyed. The total number of ADs prescriptions dispensed during COVID-19 pandemic (January to December 2020) were 78 million, 4 million more than in 2019 that costed NHS England £ 139 million more than in 2019. Sertraline, an SSRI antidepressant drug, alone accounted for an extra £113 million during 2020 than in 2019. The peak dispensing for ADs was observed in March 2020 while the total costs for AD drugs peaked in April 2020. The rising prescription costs for ADs during COVID-19 pandemic is a potential cause of concern, in particular the increasing use in adolescents and younger adults needs attention, who are at a higher risk of life-threatening adverse drug reactions.

2019冠状病毒病(COVID-19)大流行期间的社会限制对精神健康构成了严重威胁,并对抗抑郁药(ad)等精神健康药物的使用产生了影响。本研究调查了COVID-19大流行期间英国各种ad的处方和成本趋势。分析2016 - 2020年所有ad处方的全国处方率和净成分成本(NIC)。2019冠状病毒病大流行期间(2020年1月至12月)发放的ADs处方总数为7800万张,比2019年多400万张,比2019年多花费1.39亿英镑。与2019年相比,仅舍曲林(一种SSRI类抗抑郁药物)在2020年的销售额就增加了1.13亿英镑。AD的调剂峰值出现在2020年3月,而AD药物的总成本在2020年4月达到峰值。在2019冠状病毒病大流行期间,ADs的处方费用不断上升,这是一个潜在的担忧原因,特别是需要关注的青少年和年轻成年人使用ADs的情况越来越多,他们面临威胁生命的药物不良反应风险更高。
{"title":"Surging trends in prescriptions and costs of antidepressants in England amid COVID-19.","authors":"Shahad A Rabeea,&nbsp;Hamid A Merchant,&nbsp;Muhammad Umair Khan,&nbsp;Chia Siang Kow,&nbsp;Syed Shahzad Hasan","doi":"10.1007/s40199-021-00390-z","DOIUrl":"https://doi.org/10.1007/s40199-021-00390-z","url":null,"abstract":"<p><p>The social restrictions amid coronavirus disease 2019 (COVID-19) pandemic have posed a serious threat to mental health and have implications in the use of medications for mental health including antidepressants (ADs). This study investigated the trends in prescriptions and costs of various ADs in England during COVID-19 pandemic. National prescribing rates and net ingredient costs (NIC) of all ADs prescriptions during 2016 to 2020 were analyed. The total number of ADs prescriptions dispensed during COVID-19 pandemic (January to December 2020) were 78 million, 4 million more than in 2019 that costed NHS England £ 139 million more than in 2019. Sertraline, an SSRI antidepressant drug, alone accounted for an extra £113 million during 2020 than in 2019. The peak dispensing for ADs was observed in March 2020 while the total costs for AD drugs peaked in April 2020. The rising prescription costs for ADs during COVID-19 pandemic is a potential cause of concern, in particular the increasing use in adolescents and younger adults needs attention, who are at a higher risk of life-threatening adverse drug reactions.</p>","PeriodicalId":10961,"journal":{"name":"Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences","volume":"29 1","pages":"217-221"},"PeriodicalIF":0.0,"publicationDate":"2021-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/s40199-021-00390-z","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25472790","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 49
Molecular docking of alpha-enolase to elucidate the promising candidates against Streptococcus pneumoniae infection. 通过α-烯醇酶的分子对接来阐明抗肺炎链球菌感染的候选药物。
Pub Date : 2021-06-01 Epub Date: 2021-02-03 DOI: 10.1007/s40199-020-00384-3
Muhammad Hassan, Atif Amin Baig, Syed Awais Attique, Shafqat Abbas, Fizza Khan, Sara Zahid, Qurat Ul Ain, Muhammad Usman, Nordin Bin Simbak, Mohammad Amjad Kamal, Hanani Ahmad Yusof

Purpose: To predict potential inhibitors of alpha-enolase to reduce plasminogen binding of Streptococcus pneumoniae (S. pneumoniae) that may lead as an orally active drug. S. pneumoniae remains dominant in causing invasive diseases. Fibrinolytic pathway is a critical factor of S. pneumoniae to invade and progression of disease in the host body. Besides the low mass on the cell surface, alpha-enolase possesses significant plasminogen binding among all exposed proteins.

Methods: In-silico based drug designing approach was implemented for evaluating potential inhibitors against alpha-enolase based on their binding affinities, energy score and pharmacokinetics. Lipinski's rule of five (LRo5) and Egan's (Brain Or IntestinaL EstimateD) BOILED-Egg methods were executed to predict the best ligand for biological systems.

Results: Molecular docking analysis revealed, Sodium (1,5-dihydroxy-2-oxopyrrolidin-3-yl)-hydroxy-dioxidophosphanium (SF-2312) as a promising inhibitor that fabricates finest attractive charges and conventional hydrogen bonds with S. pneumoniae alpha-enolase. Moreover, the pharmacokinetics of SF-2312 predict it as a therapeutic inhibitor for clinical trials. Like SF-2312, phosphono-acetohydroxamate (PhAH) also constructed adequate interactions at the active site of alpha-enolase, but it predicted less favourable than SF-2312 based on binding affinity.

Conclusion: Briefly, SF-2312 and PhAH ligands could inhibit the role of alpha-enolase to restrain plasminogen binding, invasion and progression of S. pneumoniae. As per our investigation and analysis, SF-2312 is the most potent naturally existing inhibitor of S. pneumoniae alpha-enolase in current time.

目的:预测潜在的α-烯醇化酶抑制剂,以减少肺炎链球菌(S. pneumoniae)的纤溶酶原结合,从而成为一种口服活性药物。肺炎链球菌仍是引起侵袭性疾病的主要病原菌。纤溶途径是肺炎链球菌侵入宿主体内并导致疾病进展的关键因素。在所有暴露的蛋白质中,α-烯醇化酶除了在细胞表面的质量较低外,还具有显著的纤溶酶原结合能力:方法:根据α-烯醇化酶的结合亲和力、能量得分和药代动力学,采用基于硅的药物设计方法评估潜在的抑制剂。结果:分子对接分析表明,α-烯醇化酶抑制剂钠与α-烯醇化酶的结合亲和力和药代动力学都很高,而α-烯醇化酶抑制剂钠与α-烯醇化酶的结合亲和力和药代动力学都很低:分子对接分析表明,(1,5-二羟基-2-氧代吡咯烷-3-基)-羟基-二氧磷酸钠(SF-2312)是一种很有前途的抑制剂,它能与肺炎双球菌α-烯醇化酶形成最吸引人的电荷和常规氢键。此外,SF-2312 的药代动力学预示着它是一种可用于临床试验的治疗抑制剂。与 SF-2312 一样,膦酰基乙酰羟肟酸酯(PhAH)也在α-烯醇化酶的活性位点上构建了充分的相互作用,但根据结合亲和力预测,它的效果不如 SF-2312:简而言之,SF-2312 和 PhAH 配体可抑制α-烯醇化酶的作用,从而抑制纤溶酶原的结合、肺炎双球菌的入侵和发展。根据我们的调查和分析,SF-2312 是目前对肺炎双球菌α-烯醇化酶最有效的天然抑制剂。
{"title":"Molecular docking of alpha-enolase to elucidate the promising candidates against Streptococcus pneumoniae infection.","authors":"Muhammad Hassan, Atif Amin Baig, Syed Awais Attique, Shafqat Abbas, Fizza Khan, Sara Zahid, Qurat Ul Ain, Muhammad Usman, Nordin Bin Simbak, Mohammad Amjad Kamal, Hanani Ahmad Yusof","doi":"10.1007/s40199-020-00384-3","DOIUrl":"10.1007/s40199-020-00384-3","url":null,"abstract":"<p><strong>Purpose: </strong>To predict potential inhibitors of alpha-enolase to reduce plasminogen binding of Streptococcus pneumoniae (S. pneumoniae) that may lead as an orally active drug. S. pneumoniae remains dominant in causing invasive diseases. Fibrinolytic pathway is a critical factor of S. pneumoniae to invade and progression of disease in the host body. Besides the low mass on the cell surface, alpha-enolase possesses significant plasminogen binding among all exposed proteins.</p><p><strong>Methods: </strong>In-silico based drug designing approach was implemented for evaluating potential inhibitors against alpha-enolase based on their binding affinities, energy score and pharmacokinetics. Lipinski's rule of five (LRo5) and Egan's (Brain Or IntestinaL EstimateD) BOILED-Egg methods were executed to predict the best ligand for biological systems.</p><p><strong>Results: </strong>Molecular docking analysis revealed, Sodium (1,5-dihydroxy-2-oxopyrrolidin-3-yl)-hydroxy-dioxidophosphanium (SF-2312) as a promising inhibitor that fabricates finest attractive charges and conventional hydrogen bonds with S. pneumoniae alpha-enolase. Moreover, the pharmacokinetics of SF-2312 predict it as a therapeutic inhibitor for clinical trials. Like SF-2312, phosphono-acetohydroxamate (PhAH) also constructed adequate interactions at the active site of alpha-enolase, but it predicted less favourable than SF-2312 based on binding affinity.</p><p><strong>Conclusion: </strong>Briefly, SF-2312 and PhAH ligands could inhibit the role of alpha-enolase to restrain plasminogen binding, invasion and progression of S. pneumoniae. As per our investigation and analysis, SF-2312 is the most potent naturally existing inhibitor of S. pneumoniae alpha-enolase in current time.</p>","PeriodicalId":10961,"journal":{"name":"Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences","volume":"29 1","pages":"73-84"},"PeriodicalIF":0.0,"publicationDate":"2021-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8149539/pdf/40199_2020_Article_384.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25329682","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Stock price reaction to the drug development setbacks in the pharmaceutical industry. 股票价格对医药行业药物开发受挫的反应。
Pub Date : 2021-06-01 Epub Date: 2021-02-04 DOI: 10.1007/s40199-020-00349-6
Silvijus Abramavičius, Alina Stundžienė, Laura Korsakova, Mantas Venslauskas, Edgaras Stankevičius

Background: Investments in pharmaceutical companies remain challenging due to the inherent uncertainties of risk assessment.

Objectives: Our paper aims to assess the impact of the drug development setbacks (DDS) on the stock price of pharmaceutical companies while taking into account the company's financial situation, pipeline size and trend of the stock price before the DDS.

Methods: The model-based clustering based on finite Gaussian mixture modeling was employed to identify the clusters of pharmaceutical companies with homogenous parameters. An artificial neural network was constructed to aid the prediction of the positive mean rate of return 120 days after the DDS.

Results: Our results reveal that a higher pipeline size and a lower rate of return before the DDS, as well as a lower ratio of the market value of the equity and the book value of the total liabilities, are associated with a positive mean rate of return 120 days after the DDS.

Conclusion: In general, the DDS have a negative impact on the company's stock price, but this risk can be minimized by investors choosing the companies that satisfy certain criteria. Graphical abstract The higher pipeline size(spip) and lower rate of return before (srr) the drug development setback (DDS) and the Market Value of Equity/Book Value of Total Liabilities ratio (sx4) are associated with a positive mean rate of return 120 days after the DDS.

背景:由于风险评估固有的不确定性,对制药公司的投资仍然具有挑战性。目的:本文旨在评估药物开发挫折(DDS)对制药公司股价的影响,同时考虑公司的财务状况、产品线规模和DDS前的股价趋势。方法:采用基于有限高斯混合建模的基于模型的聚类方法,对具有均匀参数的医药企业聚类进行识别。构建了人工神经网络来帮助预测DDS后120天的正平均收益率。结果:我们的研究结果显示,在DDS之前,更高的管道规模和更低的收益率,以及更低的股权市值与总负债账面价值的比率,与DDS后120天的平均收益率呈正相关。结论:总的来说,DDS对公司的股价有负面影响,但投资者可以通过选择满足一定标准的公司来降低这种风险。较高的管道规模(spip)和药物开发挫折(DDS)前较低的收益率(srr)以及总负债的账面价值/市值比率(sx4)与DDS后120天的平均收益率呈正相关。
{"title":"Stock price reaction to the drug development setbacks in the pharmaceutical industry.","authors":"Silvijus Abramavičius,&nbsp;Alina Stundžienė,&nbsp;Laura Korsakova,&nbsp;Mantas Venslauskas,&nbsp;Edgaras Stankevičius","doi":"10.1007/s40199-020-00349-6","DOIUrl":"https://doi.org/10.1007/s40199-020-00349-6","url":null,"abstract":"<p><strong>Background: </strong>Investments in pharmaceutical companies remain challenging due to the inherent uncertainties of risk assessment.</p><p><strong>Objectives: </strong>Our paper aims to assess the impact of the drug development setbacks (DDS) on the stock price of pharmaceutical companies while taking into account the company's financial situation, pipeline size and trend of the stock price before the DDS.</p><p><strong>Methods: </strong>The model-based clustering based on finite Gaussian mixture modeling was employed to identify the clusters of pharmaceutical companies with homogenous parameters. An artificial neural network was constructed to aid the prediction of the positive mean rate of return 120 days after the DDS.</p><p><strong>Results: </strong>Our results reveal that a higher pipeline size and a lower rate of return before the DDS, as well as a lower ratio of the market value of the equity and the book value of the total liabilities, are associated with a positive mean rate of return 120 days after the DDS.</p><p><strong>Conclusion: </strong>In general, the DDS have a negative impact on the company's stock price, but this risk can be minimized by investors choosing the companies that satisfy certain criteria. Graphical abstract The higher pipeline size(spip) and lower rate of return before (srr) the drug development setback (DDS) and the Market Value of Equity/Book Value of Total Liabilities ratio (sx4) are associated with a positive mean rate of return 120 days after the DDS.</p>","PeriodicalId":10961,"journal":{"name":"Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences","volume":"29 1","pages":"1-11"},"PeriodicalIF":0.0,"publicationDate":"2021-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/s40199-020-00349-6","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25330255","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Hyperpigmentation, severe alopecia, and six days of instability in a case of severe methotrexate hypersensitivity reaction. 严重甲氨蝶呤过敏反应的色素沉着、严重脱发和6天不稳定。
Pub Date : 2021-06-01 Epub Date: 2021-01-06 DOI: 10.1007/s40199-020-00379-0
Mahan Shafie, Mahsa Abbaszadeh, Farnaz Sharifi

Introduction: Ectopic pregnancy (EP) is an emergency condition in the gynecologic field. Methotrexate (MTX) is a drug of choice for the medical treatment of EP. Severe adverse events are rare among patients treated with MTX for this condition.

Reason for report: We describe a woman with severe multi-organ involvement experiencing about six days of instability after treatment with just a single-dose MTX for EP. This life-threatening condition is not common with a single dose of MTX. A 30-year-old healthy woman was treated medically with MTX for an EP. Three days later the patient was admitted to the emergency department of our hospital with generalized pustular rashes, alopecia, hyperpigmentation, nausea and vomiting, oral ulcers, and raised Creatinine level. Four days later due to pancytopenia, fever, and loss of consciousness, she was transferred to the intensive care unit and was intubated.

Outcome: After 38 days of hospitalization, treatment was successful with leucovorin and supportive care and the patient's symptoms and clinical manifestations were regressed.

简介:异位妊娠(EP)是妇科领域的一种紧急情况。甲氨蝶呤(MTX)是EP医学治疗的首选药物。严重的不良事件在接受甲氨蝶呤治疗的患者中是罕见的。报告原因:我们描述了一位患有严重多器官受累的女性,在接受单剂量MTX治疗EP后,出现了大约6天的不稳定。这种危及生命的情况在单剂量甲氨蝶呤中并不常见。一名30岁的健康女性因EP用甲氨蝶呤治疗。3天后,患者因全身脓疱疹、脱发、色素沉着、恶心呕吐、口腔溃疡、肌酐水平升高而入住我院急诊科。4天后因全血细胞减少、发热、意识丧失,转至重症监护室插管。结果:住院38天后,亚叶酸钙治疗成功,患者的症状和临床表现得到缓解。
{"title":"Hyperpigmentation, severe alopecia, and six days of instability in a case of severe methotrexate hypersensitivity reaction.","authors":"Mahan Shafie,&nbsp;Mahsa Abbaszadeh,&nbsp;Farnaz Sharifi","doi":"10.1007/s40199-020-00379-0","DOIUrl":"https://doi.org/10.1007/s40199-020-00379-0","url":null,"abstract":"<p><strong>Introduction: </strong>Ectopic pregnancy (EP) is an emergency condition in the gynecologic field. Methotrexate (MTX) is a drug of choice for the medical treatment of EP. Severe adverse events are rare among patients treated with MTX for this condition.</p><p><strong>Reason for report: </strong>We describe a woman with severe multi-organ involvement experiencing about six days of instability after treatment with just a single-dose MTX for EP. This life-threatening condition is not common with a single dose of MTX. A 30-year-old healthy woman was treated medically with MTX for an EP. Three days later the patient was admitted to the emergency department of our hospital with generalized pustular rashes, alopecia, hyperpigmentation, nausea and vomiting, oral ulcers, and raised Creatinine level. Four days later due to pancytopenia, fever, and loss of consciousness, she was transferred to the intensive care unit and was intubated.</p><p><strong>Outcome: </strong>After 38 days of hospitalization, treatment was successful with leucovorin and supportive care and the patient's symptoms and clinical manifestations were regressed.</p>","PeriodicalId":10961,"journal":{"name":"Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences","volume":"29 1","pages":"205-209"},"PeriodicalIF":0.0,"publicationDate":"2021-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/s40199-020-00379-0","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39138981","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 5
Withdrawal reasons of randomized controlled trials on type 2 diabetes: a systematic review. 2 型糖尿病随机对照试验的退出原因:系统综述。
Pub Date : 2021-06-01 Epub Date: 2021-01-02 DOI: 10.1007/s40199-020-00380-7
Shahrzad Mohseni, Ozra Tabatabaei-Malazy, Maryam Peimani, Hanieh-Sadat Ejtahed, Mehrnoosh Khodaeian, Elahe Nazeri, Zahra Nouhi, Kajal Khodamoradi, Maryam Aboeerad, Bagher Larijani

Purpose: Type 2 diabetes mellitus (T2DM) is the subject of numerous randomized controlled trials (RCTs). The validity of RCTs may be threatened by attrition bias due to the discontinuation of the study. The aim of this systematic review is to evaluate the reasons of patient's withdrawal from these RCTs.

Methods: A systematic literature search on PubMed, Cochrane Library, Web of Science, and Scopus databases was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow diagram. The aim was to obtain all relevant blinded RCTs published before January 2017 in which the effectiveness of synthetic drugs, vitamins/minerals were compared to that of placebo or active control in T2DM. The quality of RCTs was assessed using the Jadad score. The frequency of withdrawal reasons was presented based on treatments with placebo/active control, national/international level of the studies, and publication year. Meta-analysis was not performed due to the heterogeneity.

Results: Overall, 1368 articles comprising of 640,780 subjects were included. In the majority of the RCTs (75.0%), the intervention and the placebo arms were compared. Most of the included studies (96%) were classified in the high-quality category (Jadad score≥3). The highest proportion of reported withdrawal cases was found in international studies, national RCTs conducted in Japan, and RCTs published in 2011. The withdrawal reasons were reported for 91,669 (63.75%) of the total 143,794 participants who had withdrawn from these studies. The main reported reasons were "adverse effects" (24.04%), "withdraw consent" (16.10%), and "missing data" (11.08%). Variations in the reported withdrawal reasons were based on the country or published year. RCTs with triple blinded design as well as those in which anti-hyperlipidemia and anti-obesity medications were applied, showed significantly higher probability of reported the withdrawal.

Conclusion: High proportion of reported discontinuation in blinded RCTs on patients with T2DM was related to drug adverse effects. Overall, the total number and reason of drop out were unsatisfactory.

目的:2 型糖尿病(T2DM)是众多随机对照试验(RCT)的主题。由于研究中止导致的自然减员偏差可能会威胁到 RCT 的有效性。本系统综述旨在评估患者退出这些 RCT 的原因:根据系统综述和元分析首选报告项目(PRISMA)流程图,在 PubMed、Cochrane 图书馆、Web of Science 和 Scopus 数据库中进行了系统文献检索。目的是获取 2017 年 1 月之前发表的所有相关盲法 RCT,这些 RCT 将合成药物、维生素/矿物质对 T2DM 的疗效与安慰剂或活性对照进行了比较。RCT的质量采用Jadad评分法进行评估。根据安慰剂/活性对照的治疗方法、研究的国内/国际水平和发表年份,列出了撤药原因的频率。由于存在异质性,因此未进行 Meta 分析:共纳入 1368 篇文章,640 780 名受试者。大部分研究(75.0%)对干预组和安慰剂组进行了比较。大部分纳入的研究(96%)被归类为高质量研究(Jadad评分≥3)。国际研究、在日本进行的全国性 RCT 研究以及 2011 年发表的 RCT 研究中报告的撤药病例比例最高。在退出这些研究的 143 794 名参与者中,有 91 669 人(63.75%)报告了退出原因。报告的主要原因是 "不良反应"(24.04%)、"撤回同意"(16.10%)和 "数据缺失"(11.08%)。报告的退出原因因国家或发表年份而异。采用三重盲法设计的研究以及使用抗高脂血症和抗肥胖药物的研究,报告停药的概率明显更高:结论:在针对 T2DM 患者的盲法研究中,报告停药的比例较高,这与药物不良反应有关。结论:在针对 T2DM 患者的盲法 RCT 中,报告的停药比例较高,这与药物不良反应有关。
{"title":"Withdrawal reasons of randomized controlled trials on type 2 diabetes: a systematic review.","authors":"Shahrzad Mohseni, Ozra Tabatabaei-Malazy, Maryam Peimani, Hanieh-Sadat Ejtahed, Mehrnoosh Khodaeian, Elahe Nazeri, Zahra Nouhi, Kajal Khodamoradi, Maryam Aboeerad, Bagher Larijani","doi":"10.1007/s40199-020-00380-7","DOIUrl":"10.1007/s40199-020-00380-7","url":null,"abstract":"<p><strong>Purpose: </strong>Type 2 diabetes mellitus (T2DM) is the subject of numerous randomized controlled trials (RCTs). The validity of RCTs may be threatened by attrition bias due to the discontinuation of the study. The aim of this systematic review is to evaluate the reasons of patient's withdrawal from these RCTs.</p><p><strong>Methods: </strong>A systematic literature search on PubMed, Cochrane Library, Web of Science, and Scopus databases was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow diagram. The aim was to obtain all relevant blinded RCTs published before January 2017 in which the effectiveness of synthetic drugs, vitamins/minerals were compared to that of placebo or active control in T2DM. The quality of RCTs was assessed using the Jadad score. The frequency of withdrawal reasons was presented based on treatments with placebo/active control, national/international level of the studies, and publication year. Meta-analysis was not performed due to the heterogeneity.</p><p><strong>Results: </strong>Overall, 1368 articles comprising of 640,780 subjects were included. In the majority of the RCTs (75.0%), the intervention and the placebo arms were compared. Most of the included studies (96%) were classified in the high-quality category (Jadad score≥3). The highest proportion of reported withdrawal cases was found in international studies, national RCTs conducted in Japan, and RCTs published in 2011. The withdrawal reasons were reported for 91,669 (63.75%) of the total 143,794 participants who had withdrawn from these studies. The main reported reasons were \"adverse effects\" (24.04%), \"withdraw consent\" (16.10%), and \"missing data\" (11.08%). Variations in the reported withdrawal reasons were based on the country or published year. RCTs with triple blinded design as well as those in which anti-hyperlipidemia and anti-obesity medications were applied, showed significantly higher probability of reported the withdrawal.</p><p><strong>Conclusion: </strong>High proportion of reported discontinuation in blinded RCTs on patients with T2DM was related to drug adverse effects. Overall, the total number and reason of drop out were unsatisfactory.</p>","PeriodicalId":10961,"journal":{"name":"Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences","volume":"29 1","pages":"39-50"},"PeriodicalIF":0.0,"publicationDate":"2021-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8149490/pdf/40199_2020_Article_380.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38773748","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effect of prevalent polychlorinated biphenyls (PCBs) food contaminant on the MCF7, LNCap and MDA-MB-231 cell lines viability and PON1 gene expression level: proposed model of binding. 流行的多氯联苯(PCBs)食品污染物对MCF7、LNCap和MDA-MB-231细胞系活力和PON1基因表达水平的影响:提出的结合模型
Pub Date : 2021-06-01 Epub Date: 2021-04-21 DOI: 10.1007/s40199-021-00394-9
Fatemeh Yazdi, Shahram Shoeibi, Mohammad Hossein Yazdi, Akram Eidi

Background: Polychlorinated biphenyls (PCBs) are a group of synthetic organic chlorine compounds known as an organic pollutant in food sources, which play important roles in malignancies. The present study aimed to investigate the direct effects of prevalent PCBs in food in hormone-responsive and non-responsive cell lines.

Methods: In the current study, MCF-7, LNCap, and MDA-MB231 cell lines were treated with serial concentrations (0.001-100 μM) of PCBs for 48 h and cell viability assessment was performed using MTT assay. The best concentration then applied and the expression level of PON1 was evaluated using real-time PCR. Besides, molecular docking was performed to determine the binding mechanism and predicted binding energies of PBCs compounds to the AhR receptor.

Results: Unlike MCF-7 and LNCap cells, the viability of MDA-MB231 cells did not significantly change by different concentrations of PCBs. Meanwhile, quantitative gene expression analysis showed that the PON1 was significantly more expressed in MCF-7 and LNCap lines treated with PCB28 and PCB101. However, the expression level of this gene in other groups and also MDA-MB231cells did not demonstrate any significantly change. Also, the results of molecular docking showed that PBCs had steric interaction with AhR receptor.

Conclusions: Current results showed that despite of hormone non-responsive cells the PCBs have a significant positive effect on hormone-responsive cell. Therefore, and regarding to the existence of PCBs contamination in food there should be serious concern about their impact on the prevalence of different malignancies which certainly should result in a standard limit for this material. This study aimed to investigate the direct effects of prevalent PCBs in food in hormone-responsive and non-responsive cell lines. Cell lines were treated with serial concentrations of PCBs and cell viability assessment was performed using MTT assay. The expression level of PON1 was evaluated using real-time PCR. Molecular docking was performed to determine the binding mechanism and predicted binding energies of PBCs compounds to the AhR receptor. PCBs contamination in food there should be serious concern about their impact on the prevalence of different malignancies which certainly should result in a standard limit for this material.

背景:多氯联苯(Polychlorinated biphenyl, PCBs)是一类合成的有机氯化合物,是食品中的一种有机污染物,在恶性肿瘤中起着重要作用。本研究旨在探讨食品中普遍存在的多氯联苯对激素反应性和非激素反应性细胞系的直接影响。方法:将MCF-7、LNCap和MDA-MB231细胞株分别用浓度为0.001 ~ 100 μM的多氯联苯处理48 h,采用MTT法测定细胞活力。采用实时荧光定量PCR法测定最佳浓度和PON1的表达水平。此外,通过分子对接来确定pbc化合物与AhR受体的结合机制并预测其结合能。结果:与MCF-7和LNCap细胞不同,不同浓度的多氯联苯对MDA-MB231细胞的活性没有显著影响。同时,定量基因表达分析显示,PCB28和PCB101处理的MCF-7和LNCap细胞系中PON1的表达量显著增加。而该基因在其他组及mda - mb231细胞中的表达水平无明显变化。分子对接结果表明,PBCs与AhR受体存在空间相互作用。结论:目前的研究结果表明,尽管对激素无反应细胞,多氯联苯对激素反应细胞有显著的积极作用。因此,考虑到食品中多氯联苯污染的存在,人们应该严重关注它们对不同恶性肿瘤患病率的影响,这当然应该导致对这种材料的标准限制。本研究旨在探讨食品中普遍存在的多氯联苯对激素反应性和非激素反应性细胞系的直接影响。用不同浓度的多氯联苯处理细胞系,用MTT法评估细胞活力。实时荧光定量PCR检测PON1的表达水平。通过分子对接来确定pbc化合物与AhR受体的结合机制并预测其结合能。食品中的多氯联苯污染应该引起人们的严重关注它们对不同恶性肿瘤患病率的影响,这当然应该导致对这种材料的标准限制。
{"title":"Effect of prevalent polychlorinated biphenyls (PCBs) food contaminant on the MCF7, LNCap and MDA-MB-231 cell lines viability and PON1 gene expression level: proposed model of binding.","authors":"Fatemeh Yazdi,&nbsp;Shahram Shoeibi,&nbsp;Mohammad Hossein Yazdi,&nbsp;Akram Eidi","doi":"10.1007/s40199-021-00394-9","DOIUrl":"https://doi.org/10.1007/s40199-021-00394-9","url":null,"abstract":"<p><strong>Background: </strong>Polychlorinated biphenyls (PCBs) are a group of synthetic organic chlorine compounds known as an organic pollutant in food sources, which play important roles in malignancies. The present study aimed to investigate the direct effects of prevalent PCBs in food in hormone-responsive and non-responsive cell lines.</p><p><strong>Methods: </strong>In the current study, MCF-7, LNCap, and MDA-MB231 cell lines were treated with serial concentrations (0.001-100 μM) of PCBs for 48 h and cell viability assessment was performed using MTT assay. The best concentration then applied and the expression level of PON1 was evaluated using real-time PCR. Besides, molecular docking was performed to determine the binding mechanism and predicted binding energies of PBCs compounds to the AhR receptor.</p><p><strong>Results: </strong>Unlike MCF-7 and LNCap cells, the viability of MDA-MB231 cells did not significantly change by different concentrations of PCBs. Meanwhile, quantitative gene expression analysis showed that the PON1 was significantly more expressed in MCF-7 and LNCap lines treated with PCB28 and PCB101. However, the expression level of this gene in other groups and also MDA-MB231cells did not demonstrate any significantly change. Also, the results of molecular docking showed that PBCs had steric interaction with AhR receptor.</p><p><strong>Conclusions: </strong>Current results showed that despite of hormone non-responsive cells the PCBs have a significant positive effect on hormone-responsive cell. Therefore, and regarding to the existence of PCBs contamination in food there should be serious concern about their impact on the prevalence of different malignancies which certainly should result in a standard limit for this material. This study aimed to investigate the direct effects of prevalent PCBs in food in hormone-responsive and non-responsive cell lines. Cell lines were treated with serial concentrations of PCBs and cell viability assessment was performed using MTT assay. The expression level of PON1 was evaluated using real-time PCR. Molecular docking was performed to determine the binding mechanism and predicted binding energies of PBCs compounds to the AhR receptor. PCBs contamination in food there should be serious concern about their impact on the prevalence of different malignancies which certainly should result in a standard limit for this material.</p>","PeriodicalId":10961,"journal":{"name":"Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences","volume":"29 1","pages":"159-170"},"PeriodicalIF":0.0,"publicationDate":"2021-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/s40199-021-00394-9","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38827678","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Optimization, in vitro release and toxicity evaluation of novel pH sensitive itaconic acid-g-poly(acrylamide)/sterculia gum semi-interpenetrating networks. 新型 pH 值敏感的衣康酸-聚丙烯酰胺/紫胶半互穿网络的优化、体外释放和毒性评估。
Pub Date : 2021-06-01 Epub Date: 2021-04-26 DOI: 10.1007/s40199-021-00395-8
Fauzia Rehman, Ikram Ullah Khan, Syed Haroon Khalid, Sajid Asghar, Muhammad Irfan, Ikrima Khalid, Akhtar Rasul, Huma Mahmood, Abid Mehmood Yousaf, Yasser Shahzad, Muhammad Mudassar, Noor Ul Amin Mohsin

Background: In recent era, pH sensitive polymeric carriers that combines the materials engineering and medicine is gaining researcher's attention as they maximizes drug concentration at site of absorption and reduces side effects for e.g. orally administered cetirizine HCl (CTZ HCl) upsets the stomach and furthermore shows high intestinal absorption. Thus, development of pH sensitive hydrogels with sufficient mechanical strength will be good candidate to address this issue.

Methods: Here, we developed pH sensitive itaconic acid-g-poly(acrylamide)/sterculia gum (IA-g-poly(AM)/sterculia gum) semi-interpenetrating network (semi-IPN) by free radical polymerization technique for intestinal delivery of CTZ HCL.

Results: Optimized formulation (I5) with 6% w/w IA showed negligible swelling at pH 1.2, and maximum swelling at pH 7.4. Solid state characterization of optimized formulation showed successful development of semi-IPN structure and incorporation of drug without any noticeable drug-carrier interaction. In vitro release study showed biphasic pH dependent release of CTZ HCl, where initial burst release was observed at acidic pH followed by sustained release at basic pH. Acute oral toxicity and histopathological studies confirmed the non-toxic nature of IA-g-poly(AM)/sterculia gum.

Conclusion: Conclusively, developed biocompatible semi-IPN hydrogels with sufficient pH sensitivity and mechanical strength could serve as a potential carrier for intestinal delivery of CTZ HCL to maximize its absorption and reduce side effects.

背景:近年来,结合材料工程学和医学的 pH 值敏感聚合物载体越来越受到研究人员的关注,因为它们能最大限度地提高药物在吸收部位的浓度并减少副作用,例如口服盐酸西替利嗪(CTZ HCl)会扰乱胃部,而且肠道吸收率很高。因此,开发具有足够机械强度的 pH 值敏感型水凝胶将是解决这一问题的好方法。方法:在此,我们采用自由基聚合技术开发了 pH 值敏感型衣康酸-聚丙烯酰胺/槲皮胶(IA-聚(AM)/槲皮胶)半互穿网络(semi-IPN),用于盐酸西替利嗪(CTZ HCL)的肠道给药:结果:含 6% w/w IA 的优化配方(I5)在 pH 值为 1.2 时的溶胀可忽略不计,而在 pH 值为 7.4 时溶胀最大。优化制剂的固态表征表明,该制剂成功地形成了半 IPN 结构,并成功地掺入了药物,没有出现任何明显的药物-载体相互作用。体外释放研究表明,盐酸 CTZ 的释放与 pH 值呈双相依赖关系,在酸性 pH 值下会出现最初的猝灭释放,随后在碱性 pH 值下会出现持续释放。急性口服毒性和组织病理学研究证实了 IA-g-poly(AM)/sterculia 胶的无毒性:结论:所开发的生物相容性半 IPN 水凝胶具有足够的 pH 值敏感性和机械强度,可作为一种潜在的载体用于 CTZ HCL 的肠道给药,从而最大限度地提高其吸收率并减少副作用。
{"title":"Optimization, in vitro release and toxicity evaluation of novel pH sensitive itaconic acid-g-poly(acrylamide)/sterculia gum semi-interpenetrating networks.","authors":"Fauzia Rehman, Ikram Ullah Khan, Syed Haroon Khalid, Sajid Asghar, Muhammad Irfan, Ikrima Khalid, Akhtar Rasul, Huma Mahmood, Abid Mehmood Yousaf, Yasser Shahzad, Muhammad Mudassar, Noor Ul Amin Mohsin","doi":"10.1007/s40199-021-00395-8","DOIUrl":"10.1007/s40199-021-00395-8","url":null,"abstract":"<p><strong>Background: </strong>In recent era, pH sensitive polymeric carriers that combines the materials engineering and medicine is gaining researcher's attention as they maximizes drug concentration at site of absorption and reduces side effects for e.g. orally administered cetirizine HCl (CTZ HCl) upsets the stomach and furthermore shows high intestinal absorption. Thus, development of pH sensitive hydrogels with sufficient mechanical strength will be good candidate to address this issue.</p><p><strong>Methods: </strong>Here, we developed pH sensitive itaconic acid-g-poly(acrylamide)/sterculia gum (IA-g-poly(AM)/sterculia gum) semi-interpenetrating network (semi-IPN) by free radical polymerization technique for intestinal delivery of CTZ HCL.</p><p><strong>Results: </strong>Optimized formulation (I5) with 6% w/w IA showed negligible swelling at pH 1.2, and maximum swelling at pH 7.4. Solid state characterization of optimized formulation showed successful development of semi-IPN structure and incorporation of drug without any noticeable drug-carrier interaction. In vitro release study showed biphasic pH dependent release of CTZ HCl, where initial burst release was observed at acidic pH followed by sustained release at basic pH. Acute oral toxicity and histopathological studies confirmed the non-toxic nature of IA-g-poly(AM)/sterculia gum.</p><p><strong>Conclusion: </strong>Conclusively, developed biocompatible semi-IPN hydrogels with sufficient pH sensitivity and mechanical strength could serve as a potential carrier for intestinal delivery of CTZ HCL to maximize its absorption and reduce side effects.</p>","PeriodicalId":10961,"journal":{"name":"Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences","volume":"29 1","pages":"171-184"},"PeriodicalIF":0.0,"publicationDate":"2021-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8149496/pdf/40199_2021_Article_395.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38907591","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Efficacy, safety, and tolerability of sublingual fentanyl orally disintegrating tablet in the treatment of breakthrough cancer pain: a randomized, double-blind, placebo-controlled study. 舌下芬太尼口腔崩解片治疗突破性癌痛的疗效、安全性和耐受性:一项随机、双盲、安慰剂对照研究。
Pub Date : 2021-06-01 Epub Date: 2021-01-21 DOI: 10.1007/s40199-020-00381-6
Masoud Hashemi, Alireza Zali, Ebrahim Golmakani, Mohammad Hossein Delshad, Mahdi Shadnoush, Mohammad-Esmaeil Akbari

Background: Breakthrough pain (BTP) is an important challenge in treatment and requires a rapid onset of action for pain control. BTP should be adequately controlled with a stable dose of a short-acting oral opioid. So far, no drug is available for the treatment of BTP in cancer patients in Iran, so we designed the first study in Iran to investigate the effect of sublingual fentanyl in relief of pain episodes in these patients.

Objective: The purpose of this study was to evaluate the efficacy and safety of sublingual fentanyl in the treatment of breakthrough pain in cancer patients.

Method: This study was a randomized double-blind placebo-controlled clinical trial in cancer patients with breakthrough pain (at least 1-4 episodes of acute pain with moderate to severe pain daily) referred to the pain clinic of Akhtar and Masih Daneshvari hospitals in 2019. The study consisted of two stages: 100 patients were selected by simple, non-random sampling and entered the open-label titration phase. The primary efficacy endpoint was the sum of pain intensity difference over 30 min post-administration. Secondary efficacy endpoints included pain intensity difference (PID) and pain relief (PR) throughout the 60-min post-dose assessment period. In the double-blind study, patients were randomly divided into two groups of placebo (n=50) and intervention (sublingual fentanyl tablet) (n=50). For evaluation of efficacy, 10 episodes were treated in each group and the results were recorded by the patient. (Clinical trial registration: IRCT20131124015515N8).

Results: A total of 100 patients entered the titration phase, primary efficacy of sublingual fentanyl was 3.5±0.6 and secondary efficacy of sublingual fentanyl (60 min, after treatment) was 0.3±0.6 which was statistically significant. In the titration phase, the treatment success rate was 100%. In the double-blind phase of the study, the pain intensity in multiple episodes showed a significant improvement at 15, 30, 45, and 60 min after drug administration (P=0.0001). The intensity of pain in each episode was significantly decreased compared to the next episode (P=0.0001). The mean frequency of pain episodes in the sublingual fentanyl group showed a significant decrease (P=0.0001). The most common adverse drug events in the titration phase were drowsiness (20%), dizziness (7%), and nausea 4%, and in the double-blind phase only drowsiness (12%). (Cancer Research Center, Shahid Beheshti University of Medical Sciences, Survey).

Conclusion: Sublingual fentanyl appears to be effective for patients with rapid-onset analgesia, has short-acting duration, is effective medication, safe, and well tolerated. It is a suitable choice in Iranian patients with chronic cancer-related pain controlled suffering from acute pain episodes related to cancer.

背景:突破性疼痛(BTP)是治疗中的一个重要挑战,需要迅速采取行动来控制疼痛。BTP应通过稳定剂量的短效口服阿片类药物得到充分控制。到目前为止,伊朗尚无药物可用于治疗BTP的癌症患者,因此我们在伊朗设计了第一个研究,研究舌下芬太尼对缓解这些患者疼痛发作的作用。目的:评价舌下芬太尼治疗癌症患者突破性疼痛的疗效和安全性。方法:本研究是一项随机双盲安慰剂对照临床试验,研究对象是2019年在Akhtar和Masih Daneshvari医院疼痛门诊转诊的突破性疼痛(每天至少1-4次急性疼痛,中度至重度疼痛)的癌症患者。研究分为两个阶段:通过简单、非随机抽样选择100例患者,进入开放标签滴定期。主要疗效终点为给药后30分钟疼痛强度差异的总和。次要疗效终点包括在给药后60分钟内疼痛强度差异(PID)和疼痛缓解(PR)。在双盲研究中,患者随机分为安慰剂组(n=50)和干预组(n=50)。为评价疗效,每组治疗10次,由患者记录治疗结果。(临床试验注册:IRCT20131124015515N8)。结果:共有100例患者进入滴定期,芬太尼舌下主要疗效为3.5±0.6,芬太尼舌下次要疗效(治疗后60 min)为0.3±0.6,差异有统计学意义。滴定期治疗成功率为100%。在研究的双盲阶段,多次发作的疼痛强度在给药后15、30、45和60分钟均有显著改善(P=0.0001)。与下一组相比,每一组的疼痛强度显著降低(P=0.0001)。舌下芬太尼组疼痛发作的平均频率显著降低(P=0.0001)。滴定期最常见的药物不良事件为嗜睡(20%)、头晕(7%)和恶心(4%),双盲期仅为嗜睡(12%)。(Shahid Beheshti医科大学癌症研究中心,调查)。结论:舌下芬太尼对速效镇痛有效,作用时间短,是一种有效、安全、耐受性好的药物。这是一个合适的选择,在伊朗患者的慢性癌症相关的疼痛控制,从急性疼痛发作相关的癌症。
{"title":"Efficacy, safety, and tolerability of sublingual fentanyl orally disintegrating tablet in the treatment of breakthrough cancer pain: a randomized, double-blind, placebo-controlled study.","authors":"Masoud Hashemi,&nbsp;Alireza Zali,&nbsp;Ebrahim Golmakani,&nbsp;Mohammad Hossein Delshad,&nbsp;Mahdi Shadnoush,&nbsp;Mohammad-Esmaeil Akbari","doi":"10.1007/s40199-020-00381-6","DOIUrl":"https://doi.org/10.1007/s40199-020-00381-6","url":null,"abstract":"<p><strong>Background: </strong>Breakthrough pain (BTP) is an important challenge in treatment and requires a rapid onset of action for pain control. BTP should be adequately controlled with a stable dose of a short-acting oral opioid. So far, no drug is available for the treatment of BTP in cancer patients in Iran, so we designed the first study in Iran to investigate the effect of sublingual fentanyl in relief of pain episodes in these patients.</p><p><strong>Objective: </strong>The purpose of this study was to evaluate the efficacy and safety of sublingual fentanyl in the treatment of breakthrough pain in cancer patients.</p><p><strong>Method: </strong>This study was a randomized double-blind placebo-controlled clinical trial in cancer patients with breakthrough pain (at least 1-4 episodes of acute pain with moderate to severe pain daily) referred to the pain clinic of Akhtar and Masih Daneshvari hospitals in 2019. The study consisted of two stages: 100 patients were selected by simple, non-random sampling and entered the open-label titration phase. The primary efficacy endpoint was the sum of pain intensity difference over 30 min post-administration. Secondary efficacy endpoints included pain intensity difference (PID) and pain relief (PR) throughout the 60-min post-dose assessment period. In the double-blind study, patients were randomly divided into two groups of placebo (n=50) and intervention (sublingual fentanyl tablet) (n=50). For evaluation of efficacy, 10 episodes were treated in each group and the results were recorded by the patient. (Clinical trial registration: IRCT20131124015515N8).</p><p><strong>Results: </strong>A total of 100 patients entered the titration phase, primary efficacy of sublingual fentanyl was 3.5±0.6 and secondary efficacy of sublingual fentanyl (60 min, after treatment) was 0.3±0.6 which was statistically significant. In the titration phase, the treatment success rate was 100%. In the double-blind phase of the study, the pain intensity in multiple episodes showed a significant improvement at 15, 30, 45, and 60 min after drug administration (P=0.0001). The intensity of pain in each episode was significantly decreased compared to the next episode (P=0.0001). The mean frequency of pain episodes in the sublingual fentanyl group showed a significant decrease (P=0.0001). The most common adverse drug events in the titration phase were drowsiness (20%), dizziness (7%), and nausea 4%, and in the double-blind phase only drowsiness (12%). (Cancer Research Center, Shahid Beheshti University of Medical Sciences, Survey).</p><p><strong>Conclusion: </strong>Sublingual fentanyl appears to be effective for patients with rapid-onset analgesia, has short-acting duration, is effective medication, safe, and well tolerated. It is a suitable choice in Iranian patients with chronic cancer-related pain controlled suffering from acute pain episodes related to cancer.</p>","PeriodicalId":10961,"journal":{"name":"Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences","volume":"29 1","pages":"51-59"},"PeriodicalIF":0.0,"publicationDate":"2021-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/s40199-020-00381-6","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38844974","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
HPLC methods for choloroquine determination in biological samples and pharmaceutical products. 高效液相色谱法测定生物样品和药品中的氯喹。
Pub Date : 2021-06-01 Epub Date: 2021-03-19 DOI: 10.1007/s40199-021-00391-y
Yugo Araújo Martins, Talita Mota Gonçalves, Renata F V Lopez

Objective: Review and assess pharmaceutical and clinical characteristics of chloroquine including high-performance liquid chromatography (HPLC)-based methods used to quantify the drug in pharmaceutical products and biological samples.

Evidence acquisition: A literature review was undertaken on the PubMed, Science Direct, and Scielo databases using the following keywords related to the investigated subject: 'chloroquine', 'analytical methods', and 'HPLC'.

Results: For more than seven decades, chloroquine has been used to treat malaria and some autoimmune diseases, such as lupus erythematosus and rheumatoid arthritis. There is growing interest in chloroquine as a therapeutic alternative in the treatment of HIV, Q fever, Whipple's disease, fungal, Zika, Chikungunya infections, Sjogren's syndrome, porphyria, chronic ulcerative stomatitis, polymorphic light eruption, and different types of cancer. HPLC coupled to UV detectors is the most employed method to quantify chloroquine in pharmaceutical products and biological samples. The main chromatographic conditions used to identify and quantify chloroquine from tablets and injections, degradation products, and metabolites are presented and discussed.

Conclusion: Research findings reported in this article may facilitate the repositioning, quality control, and biological monitoring of chloroquine in modern pharmaceutical dosage forms and treatments.

目标:审查和评估氯喹的药物和临床特性,包括用于定量检测药品和生物样本中药物含量的高效液相色谱法:回顾并评估氯喹的药物和临床特性,包括用于定量检测药品和生物样本中药物含量的高效液相色谱法(HPLC):在 PubMed、Science Direct 和 Scielo 数据库中使用以下与调查主题相关的关键词进行文献综述:"氯喹"、"分析方法 "和 "高效液相色谱法":七十多年来,氯喹一直被用于治疗疟疾和一些自身免疫性疾病,如红斑狼疮和类风湿性关节炎。氯喹作为一种替代疗法,用于治疗艾滋病毒、Q 热、威普尔氏病、真菌、寨卡病毒、基孔肯雅病毒感染、Sjogren 综合征、卟啉症、慢性溃疡性口炎、多形性光糜烂和不同类型的癌症,受到越来越多的关注。高效液相色谱法与紫外检测器联用是定量检测药品和生物样本中氯喹含量的最常用方法。本文介绍并讨论了用于鉴定和定量片剂和注射剂中的氯喹、降解产物和代谢物的主要色谱条件:本文报告的研究成果可促进氯喹在现代药物剂型和治疗方法中的重新定位、质量控制和生物监测。
{"title":"HPLC methods for choloroquine determination in biological samples and pharmaceutical products.","authors":"Yugo Araújo Martins, Talita Mota Gonçalves, Renata F V Lopez","doi":"10.1007/s40199-021-00391-y","DOIUrl":"10.1007/s40199-021-00391-y","url":null,"abstract":"<p><strong>Objective: </strong>Review and assess pharmaceutical and clinical characteristics of chloroquine including high-performance liquid chromatography (HPLC)-based methods used to quantify the drug in pharmaceutical products and biological samples.</p><p><strong>Evidence acquisition: </strong>A literature review was undertaken on the PubMed, Science Direct, and Scielo databases using the following keywords related to the investigated subject: 'chloroquine', 'analytical methods', and 'HPLC'.</p><p><strong>Results: </strong>For more than seven decades, chloroquine has been used to treat malaria and some autoimmune diseases, such as lupus erythematosus and rheumatoid arthritis. There is growing interest in chloroquine as a therapeutic alternative in the treatment of HIV, Q fever, Whipple's disease, fungal, Zika, Chikungunya infections, Sjogren's syndrome, porphyria, chronic ulcerative stomatitis, polymorphic light eruption, and different types of cancer. HPLC coupled to UV detectors is the most employed method to quantify chloroquine in pharmaceutical products and biological samples. The main chromatographic conditions used to identify and quantify chloroquine from tablets and injections, degradation products, and metabolites are presented and discussed.</p><p><strong>Conclusion: </strong>Research findings reported in this article may facilitate the repositioning, quality control, and biological monitoring of chloroquine in modern pharmaceutical dosage forms and treatments.</p>","PeriodicalId":10961,"journal":{"name":"Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences","volume":"29 1","pages":"223-239"},"PeriodicalIF":0.0,"publicationDate":"2021-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8149527/pdf/40199_2021_Article_391.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25505207","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1